dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Moreno, Christophe |
dc.contributor.author | Sarrazin, Christoph |
dc.contributor.author | Gschwantler, Michael |
dc.contributor.author | Foster, Graham R. |
dc.contributor.author | Craxi, Antonio |
dc.contributor.author | Asselah, Tarik |
dc.contributor.author | Buti Ferret, Maria |
dc.date.accessioned | 2021-04-22T07:54:10Z |
dc.date.available | 2021-04-22T07:54:10Z |
dc.date.issued | 2017-01-05 |
dc.identifier.citation | Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, et al. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. Grebely J, editor. PLoS One. 2017 Jan 5;12(1):e0168713. |
dc.identifier.issn | 1932-6203 |
dc.identifier.uri | https://hdl.handle.net/11351/5893 |
dc.description | Esdeveniments adversos; Malalties del fetge; Teràpia amb inhibidors de la proteasa |
dc.description.sponsorship | The study described in this manuscript (HPC3014; NCT01846832) was sponsored by Janssen Pharmaceuticals. The funder was involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Editorial support was provided by Ian Grieve (Medical Writer at Zoetic Science, an Ashfield Company, part of UDG Healthcare plc, Macclesfield, UK); this support was funded by Janssen Pharmaceuticals. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
dc.language.iso | eng |
dc.publisher | Public Library of Science |
dc.relation.ispartofseries | PLoS ONE;12(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Fetge - Malalties |
dc.subject | Medicaments - Administració |
dc.subject.mesh | Liver Diseases |
dc.subject.mesh | /drug therapy |
dc.title | Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1371/journal.pone.0168713 |
dc.subject.decs | enfermedades hepáticas |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0168713 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Asselah T] Hepatology Department, Beaujon Hospital, University of Paris, Paris, France. [Moreno C] CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium. [Sarrazin C] Johann Wolfgang Goethe University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany. [Gschwantler M] Department of Internal Medicine IV, Wilhelminenspital, Vienna, Austria. [Foster GR] Queen Mary Hospital, University of London, Barts Health, London, United Kingdom. [Craxí A] Sezione di Gastroenterologia & Epatologia, Di.Bi.M.I.S., University of Palermo, Palermo, Italy. [Buti M] Unitat d'Hepatologia, Vall d’Hebron Hospital, Barcelona, Spain. Ciberehd del Instituto Carlos III |
dc.identifier.pmid | 28056030 |
dc.identifier.wos | 000391639100010 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |